GlassScriptPhysician profile
Denise L Baker
NPI 1386660298
$3,679.96
in general payments reported to CMS, 2019-2025
14 companies · $546 in 2025
The $546 reported for 2025 was more than what 85% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $790 · 2020: $439 · 2021: $758 · 2022: $20.26 · 2023: $663 · 2024: $462 · 2025: $546.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,672.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,671.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $2,751.26 | 2020-2025 | Xeomin |
| Therapeuticsmd, INC. | $259.58 | 2019 | |
| Allergan, INC. | $145.43 | 2019 | |
| Astellas Pharma US INC | $99.99 | 2019 | |
| Viiv Healthcare Company | $93.59 | 2019 | |
| Galderma Laboratories, L.P. | $74.56 | 2019-2021 | |
| Amag Pharmaceuticals, INC. | $74.04 | 2019 | |
| Cardiovascular Systems INC. | $53.35 | 2019 | |
| Novartis Pharmaceuticals Corporation | $29.31 | 2025 | |
| Sun Pharmaceutical Industries INC. | $20.34 | 2020 | |
| Novo Nordisk INC | $20.26 | 2022 | |
| Duchesnay USA Incorporated | $20.15 | 2019 | |
| Alfasigma USA, INC. | $19.36 | 2020 | |
| Millicent US INC | $18.74 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Denise Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.